Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

Documenti analoghi

• The role of trephine bone marrow biopsies in the era of measurable residual disease — Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
  di: Nadine Kutsch, et al.
  Pubblicazione: (2024)
• 840 | CLL‐RT1 EXTENSION TRIAL: ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD1 INHIBITOR, PLUS SONROTOCLAX, A BCL2 INHIBITOR, FOR TREATMENT OF RICHTER TRANSFORMATION
  di: O. Al‐Sawaf, et al.
  Pubblicazione: (2025)
• Inferences of associated latent variables by the observable test scores
  di: Rudy Ligtvoet
  Pubblicazione: (2025)
• Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial
  di: Paula Cramer, et al.
  Pubblicazione: (2024)
• Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations
  di: Petra Langerbeins, et al.
  Pubblicazione: (2024)